Systematic review of sarcopenia in inflammatory bowel disease

Fatani, H; Olaru, Adina; Stevenson, Rebecca; Alharazi, Waad; Jafer, Ayman; Atherton, Philip J.; Brook, Matthew S.; Moran, Gordon W

doi:10.1016/j.clnu.2023.05.002

Cited by 21 publications

(14 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among these, most of the patients with myopenia either had a normal BMI (49%) or were overweight and obese (15.7%). 104 A similar finding was noted in a cohort of IBD patients who were initiated on anti-TNF therapy: 41.5% of patients with myopenia had normal BMI and 19.5% were considered to be overweight or obese. 105 A study of body composition in patients with CD suggests that BMI has only an intermediate correlation with skeletal muscle index (SMI) (r was between 0.5 and 0.7).…”

Section: Nutrition Status and Sarcopenia In Ibdsupporting

confidence: 69%

“…A study on nutritional status and body composition of a cohort of 88 CD patients revealed that malnourishment is prevalent (21.6%), but a greater number of patients were overweight and obese (32.8%). Among these, most of the patients with myopenia either had a normal BMI (49%) or were overweight and obese (15.7%) 104 . A similar finding was noted in a cohort of IBD patients who were initiated on anti‐TNF therapy: 41.5% of patients with myopenia had normal BMI and 19.5% were considered to be overweight or obese 105 .…”

Section: Nutrition Status and Sarcopenia In Ibdsupporting

confidence: 58%

“…106 Further analysis showed that malnutrition had no significant effect on adverse outcomes (composite of surgery, hospitalization, abscess formation) but patients with myopenia had a significantly higher rate of adverse outcomes compared with those without myopenia (surgery: 63.3% vs. 27.8%, P = 0.001; hospitalizations: 61.2% vs. 36.1%, P = 0.022; abscesses: 51.0% vs. 16.7%, P = 0.001); myopenia and visceral obesity but not BMI were independent predictors for the need of surgery. 104 In contrast to the above findings, a study of myopenia (measured on CT at L3 level) in relation to disease activity (CDAI score) in patients with CD showed no significant difference in the prevalence of sarcopenia across varied disease activity (47.4%-moderately active, 42.1%-mildly active, and 10.5%-remission, P = 0.228). However, they have noted that the disease course was more aggressive in those with myopenia (31.6% vs. 16%, P = 0.06) and a higher requirement of surgery in patients with myopenia (31.6% vs. 4%, P = 0.01).…”

Section: Nutrition Status and Sarcopenia In Ibdmentioning

confidence: 63%

“…A retrospective study measured adverse outcomes, a composite of death or need for surgery, in patients with CD who underwent CT and found out that although nonsignificant the adverse event rate was higher numerically in patients with myopenia than those without (52% vs. 37.4%) 106 . Further analysis showed that malnutrition had no significant effect on adverse outcomes (composite of surgery, hospitalization, abscess formation) but patients with myopenia had a significantly higher rate of adverse outcomes compared with those without myopenia (surgery: 63.3% vs. 27.8%, P = 0.001; hospitalizations: 61.2% vs. 36.1%, P = 0.022; abscesses: 51.0% vs. 16.7%, P = 0.001); myopenia and visceral obesity but not BMI were independent predictors for the need of surgery 104 . In contrast to the above findings, a study of myopenia (measured on CT at L3 level) in relation to disease activity (CDAI score) in patients with CD showed no significant difference in the prevalence of sarcopenia across varied disease activity (47.4%—moderately active, 42.1%—mildly active, and 10.5%—remission, P = 0.228).…”

Section: Nutrition Status and Sarcopenia In Ibdmentioning

confidence: 94%

See 3 more Smart Citations

Sarcopenia and frailty in inflammatory bowel disease: Emerging concepts and evidence

Neelam,

Sharma,

Sharma

2024

JGH Open

View full text Add to dashboard Cite

Sarcopenia is a condition marked by progressive loss of skeletal muscle mass and function while frailty is a multidimensional concept characterized by diminished physiological reserve and increased vulnerability to stressors. Both of these were previously considered as related to aging and shown to impact the quality of life and carry prognostic significance. Emerging data show that both sarcopenia and frailty carry similar relevance in chronic illness. Inflammatory bowel disease (IBD) is characterized by chronic inflammation of the gastrointestinal tract and malnourishment, both of which contribute to the development of sarcopenia by increasing protein breakdown and reducing protein synthesis. The coexistence of frailty further compounds the clinical complexity of IBD patients. Published evidence suggests a bidirectional association with IBD contributing to muscle wasting, while the resultant sarcopenia and frailty could further exacerbate the disease course. Sarcopenia and frailty are independently associated with adverse outcomes, including hospitalizations, increased surgical interventions, and surgical complications. As therapeutic strategies for IBD evolve, understanding the nuanced relationship between inflammatory bowel disease, sarcopenia, and frailty is crucial for devising holistic management. Comprehensive care should encompass not only disease‐modifying therapies but also interventions targeting frailty and sarcopenia, as they have been shown to have a significant impact not only on the disease course but also on the quality of life. Future research could focus on further elucidating underlying mechanisms, simple screening strategies, and developing targeted interventions to improve the overall quality of life for individuals grappling with the complex interplay of IBD, sarcopenia, and frailty.

show abstract

Section: Nutrition Status and Sarcopenia In Ibdsupporting

confidence: 69%

Section: Nutrition Status and Sarcopenia In Ibdsupporting

confidence: 58%

Section: Nutrition Status and Sarcopenia In Ibdmentioning

confidence: 63%

Section: Nutrition Status and Sarcopenia In Ibdmentioning

confidence: 94%

See 2 more Smart Citations

Sarcopenia and frailty in inflammatory bowel disease: Emerging concepts and evidence

Neelam,

Sharma,

Sharma

2024

JGH Open

View full text Add to dashboard Cite

show abstract

“…IBD significantly impacts patients' quality of life and social functioning, both physically and emotionally. For example, muscle atrophy is common among IBD patients, with 42% experiencing myopenia, 34% pre-sarcopenia, and 17% sarcopenia, leading to increased risks of therapy failure, postoperative complications, and low body mass index [ 40 ]. Additionally, the prevalence of depression (25.2%) and anxiety (32.1%) among IBD patients further exacerbates the burden on healthcare systems [ 41 ].…”

Section: Reviewmentioning

confidence: 99%

The Role of Gut Microbiome in the Pathogenesis and the Treatment of Inflammatory Bowel Diseases

Vidal-Gallardo,

Méndez Benítez,

Flores Rios

et al. 2024

Cureus

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, is a chronic condition characterized by inflammation of the gastrointestinal tract. Its exact cause is unknown, but it's thought to result from a dysregulated immune response influenced by various factors, including changes in the intestinal microbiota, diet, lifestyle, and genetics. The gut microbiome, consisting of diverse microorganisms, plays a crucial role in maintaining physiological balance, with its disruption leading to inflammatory responses typical of IBD. Treatments primarily aim at symptom control, employing immunomodulators, corticosteroids, and newer approaches like probiotics, prebiotics, fecal transplants, and dietary modifications, all focusing on leveraging the microbiota's potential in disease management. These strategies aim to restore the delicate balance of the gut microbiome, typically altered in IBD, marked by a decrease in beneficial bacteria and an increase in harmful pathogens. This review underscores the importance of the gut microbiome in the pathogenesis and treatment of IBD, highlighting the shift towards personalized medicine and the necessity for further research in understanding the complex interactions between the gut microbiota, immune system, and genetics in IBD. It points to the potential of emerging treatments and the importance of a multifaceted approach in managing this complex and challenging disease.

show abstract

Expanding ultrasound horizons in inflammatory bowel disease: Beyond the bowel

Sousa,

Rodrigues

2024

UEG Journal

View full text Add to dashboard Cite

Sarcopenia is a syndrome of increasing importance due to its increasing prevalence and significant personal, social and economic impact. 1,2 Recent definitions characterize it as a syndrome marked by reductions in both skeletal muscle mass and strength. 2 Although conventionally linked with the elderly, sarcopenia can also occur in younger subjects secondary to other pathologic conditions, as is the case of inflammatory bowel disease (IBD). 3,4 In IBD, sarcopenia is associated with adverse clinical outcomes including heightened risk of treatment failure, age-related mortality, and post-operative complications. 3,4 Health implications of sarcopenia underscore the necessity for screening and early detection. While various methods exist-such as magnetic resonance imaging (MRI), computed tomography (CT), dualenergy X-ray absorptiometry (DXA) and bioelectrical impedance analysis (BIA)-limitations impede their routine use. The ideal tool should be easily accessible, cost-effective, and reproducible across different clinical settings. Ultrasound is emerging as an alternative for ject of further research. Finally, prospective studies with serial assessment of muscle health and disease activity should be conducted to demonstrate the impact of the latter in the development of sarcopenia, and to test different therapeutic interventions.

show abstract

Systematic review of sarcopenia in inflammatory bowel disease

Cited by 21 publications

References 44 publications

Sarcopenia and frailty in inflammatory bowel disease: Emerging concepts and evidence

Sarcopenia and frailty in inflammatory bowel disease: Emerging concepts and evidence

The Role of Gut Microbiome in the Pathogenesis and the Treatment of Inflammatory Bowel Diseases

Expanding ultrasound horizons in inflammatory bowel disease: Beyond the bowel

Contact Info

Product

Resources

About